SYRACUSE, N.Y., Sept. 23, 2020 /PRNewswire/ -- Quadrant Biosciences Inc., a developer of epigenetic diagnostic tools, announced today that it has received an Emergency Use Authorization (EUA) from the ...

The companies will work to integrate Prevencio's protein-based blood tests into Quadrant's care pathways to better translate the results into clinical action and measure outcomes.

Quadrant Biosciences said late Wednesday it received an emergency approval from the Food and Drug Administration for a saliva-based COVID-19 test. The privately held Syracuse, N.Y.-based company ...